JXJinping Xu

Jinping Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinping Xu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correlates of patient-centered discussions on colorectal cancer screening: results from the health information national trends survey (HINTS)

    by Aisha T. Langford, Margaret Sena Akpo, Nancy Buderer, Jinping Xu

    Purpose In 2021, the U.S. Preventive Services Task Force lowered the recommended start age for colorectal cancer (CRC) screening to 45 years. In this study, we examined sociodemographic and health-related factors associated with U.S. adults being told about different CRC screening tests by health professionals. Methods We conducted a cross-sectional, secondary analysis of the 2022 Health Information National Trends Survey. The main outcome was, “Has a doctor or other health professional ever told you there are a few different tests to detect colorectal cancer?” We compared “yes” responses (n = 1945) to “no” or “never” discussed responses combined (n = 878). Results In the multivariable logistic regression model, adults aged 45–49 years and females had lower odds of being told about CRC screening tests compared to adults aged 50–75 years and males, respectively. Conversely, participants in excellent/very good health compared to those in fair/poor health, those with a history of diabetes compared to no diabetes, and those with higher household income ranges compared with 0 to $19,999 had higher odds of being told about CRC screening tests. Conclusion Increasing CRC screening test awareness, particularly among females and adults aged 45 to 49, may strengthen patient-clinician communication and promote earlier CRC detection.


  • Open Access

    Diabetes mellitus and hyperglycemia control on the risk of colorectal adenomatous polyps: a retrospective cohort study

    by Katarzyna Budzynska, Daniel Passerman, Denise White-Perkins, Della A. Rees, Jinping Xu, Lois Lamerato, Susan Schooley

    Colorectal cancer (CRC) develops from colorectal adenomatous polyps. This study is to determine if diabetes mellitus (DM), its treatment, and hemoglobin A1c (HbA1c) level are associated with increased risk of colorectal adenomatous polyps. This was a retrospective cohort study that included patients who had at least one colonoscopy and were continuously enrolled in a single managed care organization during a 10-year period (2002–2012). Of these patients (N = 11,933), 1800 were randomly selected for chart review to examine the details of colonoscopy and pathology findings and to confirm the diagnosis of DM. Multivariable logistic regression analyses were performed to assess the associations between DM, its treatment, HbA1c level and adenomatous polyps (our main outcome). Among the total of 11,933 patients with a mean (standard deviation) age of 56 (± 8.8) years, 2306 (19.3%) had DM and 75 (0.6%) had CRC. Among the 1800 under chart review, 445 (24.7%) had DM, 11 (0.6%) had CRC and 537 (29.8%) had adenomatous polyps. In bivariate analysis, patients with DM had 1.45 odds of developing adenomatous polyps compared to those without DM. This effect was attenuated (odds ratio = 1.25, 95% CI: 0.96–1.62, p = 0.09) after adjusting for confounders such as age, gender, race/ethnicity, and body mass index. There was no significant association between type or duration of DM treatment or HbA1c level and adenomatous polyps. Our study confirmed the known increased risk of adenomatous polyps with advancing age, male gender, Hispanic race/ethnicity and higher body mass index. Although it suggested an association between DM and adenomatous polyps, a statistically significant association was not observed after controlling for other potential confounders. Further studies with a larger sample size are needed to further elucidate this relationship.